In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Rare Disease: 2025 in review
2025 has been a year of progress in the rare disease (RD) space. At CRA, we continue to leverage our cross-functional expertise in strategy, policy, analytics,...